title: Effect of infliximab on experimentally induced otitis media in rats.
abstract: OBJECTIVE
  We performed a prospective randomized and controlled animal study to investigate the effects of infliximab on experimental otitis media in rats.
  
  
  METHODS
  Seventy-two Sprague-Dawley rats were randomly allocated to 3 study groups and 1 control group. Infliximab was injected intravenously. Histopathologic changes were determined by hematoxylin-eosin staining. Fluorescence microscopy was performed to examine the leakage of the exudates. Vascular permeability was measured by the Evans blue dye technique.
  
  
  RESULTS
  In comparison with the control group, we found significant differences in the extent of middle ear mucosa without active inflammation and the presence of reparable lesions in all study groups treated with infliximab. A significant reduction of extravasated Evans blue dye in all study group animals was found as compared with the control group animals.
  
  
  CONCLUSIONS
  This study suggests that the monoclonal tumor necrosis factor alpha antibody, infliximab, can reduce inflammatory activity in experimental otitis media in rats.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
authors.forename: Dong-Hee
authors.initials: DH
authors.lastname: Lee
authors.forename: Sang-Won
authors.initials: SW
authors.lastname: Yeo
authors.forename: Ki-Hong
authors.initials: KH
authors.lastname: Chang
authors.forename: So-Young
authors.initials: SY
authors.lastname: Park
authors.forename: Jeong-Hoon
authors.initials: JH
authors.lastname: Oh
authors.forename: Jae-Hyun
authors.initials: JH
authors.lastname: Seo
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D002199:Capillary Permeability; D004432:Ear, Middle / Q000187:drug effects / Q000473:pathology; D005070:Evans Blue; D000069285:Infliximab; D007275:Injections, Intravenous; D008856:Microscopy, Fluorescence; D009092:Mucous Membrane / Q000187:drug effects / Q000473:pathology; D010033:Otitis Media / Q000188:drug therapy*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005070:Evans Blue; D000069285:Infliximab